Table 1.
The effect of intravitreal and topical application of CAD27 on retinal function assessed by electroretinography (ERG).
| ERG Parameters | Vehicle | Lucentis® (IVI) | CAD27 (10 μg, IVI) |
CAD27 (20 μg, IVI) |
CAD27 (10 μg/mL, TA) |
CAD27 (20 μg/mL, TA) |
p Value |
|---|---|---|---|---|---|---|---|
| a-wave amplitude, μV | −128.6 ± 11.1 | −145.7 ± 10.9 | −161.4 ± 14.7 | −142.1 ± 10.2 | −159.9 ± 10.3 | −163.3 ± 9.2 | 0.1557 |
| a-wave latency, ms | 19.7 ± 0.7 | 20.0 ± 0.6 | 17.8 ± 0.9 | 19.8 ± 1.0 | 18.2 ± 0.5 | 18.7 ± 0.4 | 0.0834 |
| b-wave amplitude μV | 296.5 ± 15.2 | 314.3 ± 20.8 | 351.1 ± 27.2 | 310.1 ± 29.7 | 336.5 ± 19.9 | 367.1 ± 22.4 | 0.1522 |
| b-wave latency, ms | 58.7 ± 1.5 | 55.1 ± 1.4 | 51.9 ± 2.2 | 52.2 ± 2.5 | 54.8 ± 1.5 | 54.2 ± 1.3 | 0.0675 |
Statistical analysis was performed using one-way ANOVA. IVI: intravitreal injection, TA: topical application.